Resources
Related Tags:
Bemis Co. Inc. (12 results)
BNET Resources
- sort by:
- Relevance
- Date
- Popularity
- Ex-Bristol-Myers Squibb official indicted for lying to feds
- WASHINGTON AFP — A former senior vice president of Bristol-Myers Squibb Company BMS has been indicted for lying about a patent deal involving the blood-thinning drug Plavix, justice officials said Wednesday. Andrew Bodnar faces up to five years in prison and a fine of more than 250,000 dollars if...
- Research articles 2008-04-23
- Otsuka to Pay More Than $4 Million to Resolve Off-Label Marketing Allegations Involving Abilify
- To: NATIONAL EDITORS Contact: U.S. Department of Justice Office of Public Affairs, +1- 202-514-2007, TDD +1-202-514-1888 WASHINGTON, March 27 /PRNewswire-USNewswire/ -- Otsuka American Pharmaceutical Inc., the U.S. subsidiary of Japanese pharmaceutical manufacturer Otsuka Pharmaceutical Co., Ltd., has agreed to pay more than $4 million to resolve allegations that it...
- Research articles 2008-03-27
- Frost & Sullivan Recognizes MIV Therapeutics for Technological Breakthroughs in Interventional Cardiology Enabled by Its HAp-based Drug Delivery Systems
- PALO ALTO, Calif. -- Based on its recent analysis of the interventional cardiology markets, Frost & Sullivan recognizes MIV Therapeutics, Inc. (OTCBB:MIVT) (Frankfurt:MIV), a leading developer of next-generation coatings and advanced drug delivery systems for cardiovascular stents and other implantable medical devices, with the 2008 North American Frost & Sullivan...
- Research articles 2008-03-13
- More supplier consolidation as OEMs strive for lighter, quieter, odour-free cars: technical trends in automotive are challenging ingenuity in the urethanes world--as the supplier and automaker sectors struggle with their commercial viability.(automotive)
- Vehicle makers are having to reinvent car engineering in areas such as cutting weight, using greener technology and lowering emissions. But, particularly in the US, these demands come at a time when the automakers are struggling. Their total market is diminishing and the transplants...
- Research articles 2007-10-01
- Bristol-Myers Squibb Pleads Guilty to Lying to the Federal Government About Deal Involving Blood-Thinning Drug
- To: AND HEALTH/MEDICAL EDITORSContact: U.S. Department of Justice, +1-202-514-2007, http:// www.usdoj.gov WASHINGTON, May 30 /PRNewswire-USNewsire/ -- The Department of Justice announced today that Bristol-Myers Squibb Company BMS has agreed to plead guilty and pay a $1 million criminal fine for lying to the federal government about a patent deal involving...
- Research articles 2007-05-30
- Daily Market Alert for Bristol-Myers Squibb Co.
- M2 PRESSWIRE-13 February 2007-Biotech News: Daily Market Alert for Bristol-Myers Squibb Co.C1994-2007 M2 COMMUNICATIONS LTD RDATE:13022007 Do you have high cholesterol? If so, you're a potential customer for Bristol-Myers Squibb BMS. The pharmaceutical giant makes platelet inhibitor Plavix and cholesterol reduction...
- Research articles 2007-02-13
- The Digica - BMS strategic offering for JD Edwards customers.
- M2 PRESSWIRE-27 July 2006-DIGICA: The Digica - BMS strategic offering for JD Edwards customersC1994-2006 M2 COMMUNICATIONS LTD RDATE:27072006 Digica and BMS Beoley Mill Software Ltd announce their strategic partnership to provide an end-to-end outsourced IT service capability for JD Edwards World...
- Research articles 2006-07-27
- US pharma giant gives up AIDS drug patent in Thailand
- BANGKOK AFP ? A US pharmaceutical firm has given up its patent in Thailand to produce a generic AIDS drug in a historic move that could see drug costs plunge, activists said. Bristol-Myers Squibb BMS reached agreement Friday to return its patent to produce the anti-retroviral drug didanosine ddi...
- Research articles 2004-01-17
- Technology Transfer: NIH-Private Sector Partnership in the Development of Taxol.
- GAO-03-829 June 4, 2003 The transfer of technology from government-funded medical research laboratories to the private sector aims to have new pharmaceuticals brought to market more efficiently than would be possible for a federal agency acting alone. Much of the pharmaceutical-related technology transfer originates with research funded by...
- Research articles 2003-07-01
- FTC gives nod to Carl Icahn for ImClone stock. (Markets: Life Sciences).(Federal Trade Commission approves stock purchase)(Brief Article)(Statistical Data Included)
- ANOTHER TWIST in the shaky $2 billion partnership between Bristol-Myers Squibb Company BMS and ImClone Systems Inc. occurred last week when the Federal Trade Commission FTC gave clearance for financier Carl C. Icahn to purchase $500 million of ImClone stock or roughly 40 percent of the...
- Research articles 2002-02-25
- Proposals to curb DTC ads being floated in Congress
- HIGHLIGHTS "High-5" for Statins, assurance of safety, efficacy. Sampling strategy: the right amount to the right docs. Formulary drug decision-- making criteria outlined. BMS follows Pfizer with Florida Medicaid deal. Direct-to-consumer DTC advertising of prescription drugs is being held responsible, in part, for...
- Research articles 2001-10-01
- Pharma shake ups may effect retail drug, eventually
- NEW YORK -- Roche, Bristol-Myers Squibb and GlaxoSmithKline all announced major company changes with significant workforce implications recently, but industry analysts said retail pharmacy need not worry--vet. Thus far, according to some analysts, these manufacturing-side changes seem to be cost-cutting measures and have left distribution relatively alone. But Mark...
- Research articles 2001-07-23
- Statement by Yale University regarding Bristol-Myers Squibb company's program to fight HIV/AIDS.
- M2 PRESSWIRE-15 March 2001-YALE UNIVERSITY: Statement by Yale University regarding Bristol-Myers Squibb company's program to fight HIV/AIDS C1994-2001 M2 COMMUNICATIONS LTD RDATE:14032001 Yale is pleased that Bristol-Myers Squibb BMS has decided to make Zerit, a Yale research discovery,...
- Research articles 2001-03-15
- Whose data is it, anyway? A look at site visitors, regulators, site owners...and the privacy policy
- As Internet users become increasingly wary about giving up personal information, and federal commissioners increasingly impatient with self-regulation, pharmaceutical web sites need to clarify what data they collect and what they do with it. The privacy policies of major U.S. pharmaceutical sites show a mix of good and bad practices,...
- Research articles 2001-02-01
- New tools assisting in ballast-care campaign
- Ballast is the foundation of track, so proper care and attention is a must to ensure a solid foundation. Those small rocks that support the ties and rails may look nondescript, but railroaders know that you ignore proper ballast care at your peril. Suppliers are introducing and upgrading systems...
- Research articles 2000-03-01
- New York Health Care signs contract with Biomedical Systems Corporation
- BROOKLYN, N.Y.--BUSINESS WIRE--March 5, 1997--New York Health Care, Inc. (NASAQ:NYHC, BSE: NYH), a licensed home health care agency, today announced that it has signed a contract with Biomedical Systems Corporation BMS. BMS, an international company headquartered in St. Louis, Missouri, is a leader in medical monitoring and...
- Research articles 1997-03-05
- Smartel Communications announces first North American licenses agreement
- MISSISSAUGA, Ontario--BUSINESS WIRE--Sept. 12, 1995--Smartel Communications Corporation, ("Smartel/the Company") of Mississauga Ontario, Canada, today announced it has entered into its first North American agreement for the licensing in Canada of the Company's proprietary system of multiple user, billing, financial administration and financial control software (the "BMS System") specifically designed...
- Research articles 1995-09-12
- BMS Is Losing Suits in Plavix-Apotex Fiasco; Another $125M Down the Toilet
- Bristol-Myers Squibb is mostly losing its Plavix securities litigation. It's 10-Q filing with the SEC says it just paid out $125 million to settle a suit over the 2006 fiasco; it settled a second suit for an undisclosed sum; and two others remain pending. by Jim Edwards
- Blog posts 2009-07-28
- Should Sanofi-Aventis Buy Bristol Myers-Squibb?
- Bristol-Myers Squibb CEO James Cornelius said in a recent earnings call that due to its healthy cash position it may be on the prowl for biotech acquisitions. That's ironic because it is looking more like BMS itself could be the company to be acquired, possibly by Sanofi-Aventis. ...
- Blog posts 2008-10-27
- Bristol-Myers Squibb Plans $2.5 Bil. in Layoffs, Cuts
- Bristol-Myers Squibb made a presentation this morning at the Credit Suisse Healthcare Conference that showed CFO John Marc-Huet wants to save the company $2.5 billion in "productivity initiatives." He's going to squeeze these out of "headcount and related costs" -- which sounds like a euphemism for layoffs. ...
- Blog posts 2008-11-13
- << Previous
- page 1 of 2
- Next >>
Content Types
Refining Tags
- Jim Edwards (11 results)
- Bristol-Myers Squibb Co. (9 results)
- Finance (6 results)
- FTC (5 results)
- Patent (4 results)
- Business Operations (4 results)
- Marketing (3 results)
- Investment (3 results)
- HEALTHCARE (3 results)
- U.S. Department of Justice (3 results)
- Litigation (3 results)
- Plavix (3 results)
- Strategy (3 results)
- Sales (3 results)
- Government (3 results)
